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Objectives: To investigate the clinicopathological characteristics and surgicl outcome of tho-
racic esophageal cancer after gastrectomy, and compare with those without gastrectomy.
Result: Among 1411 esophageal cancer patients who underwent curative operation, 48
(3.4%) had a history of distal gastrectomy, the interval between gastrectomy and esopha-
gectomy was significantly shorter in those gastrectomized for gastric cancer
(11.5  8.2 years) than for peptic ulcer (24.6  9.2 years), the proportion of lower-third tu-
mors and multiple esophageal cancer was significantly higher compared with that of
the non-gastrectomized patients (50.0% vs. 33.1%, P ¼ 0.033; 14.6% vs. 5.3%, P ¼ 0.006, re-
spectively), this increase was more pronounced after Billroth I vs. Billroth II gastrectomy.
Pathologically, the esophageal cancers after gastrectomy frequently showed expansive
growth pattern (39.6%), while those without gastrectomy dominantly showed infiltrative
growth pattern (40.3%) (P ¼ 0.012), the coexisting lesions showed well-differentiated squa-
mous cell carcinoma confined within the superficial mucosal layer. Compared with the
non-gastrectomized patients, the operative time (311.2  86.0 vs. 263.7  84.9 min;
P < 0.001) was longer and blood loss (4.38  1.33 vs. 3.57  1.82 IU; P ¼ 0.003) was more,
the postoperative hospital stay was significantly longer in gastrectomized patients (me-
dian 69 days vs. 40 days, P < 0.001). The overall 1, 3, 5, 10-year survival of gastrectomized
and non-gastrectomized patients were similar, and their cause-specific 5-year survival
were 65% vs. 44% (P ¼ 0.992).
Conclusions: Gastrectomy (especially the Billroth I) precipitated subsequent chronic gastro-
esophageal reflux and induced the development of squamous dysplasia and carcinoma at
multiple locations in the esophagus. Surgical treatment of the gastrectomized patients
should be considered as a reliable therapeutic modality because of favorable prognoses.
ª 2008 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction cancer.1–3 The most troublesome problem about them is thatPatients with a history of distal gastrectomy are an interesting
group to study because duodenogastroesophageal reflux is
thought to be common and the reflux of gastroduodenal
contents has the carcinogenetic effects on the esophageal155 1799.
.H. Li).
hed by Elsevier Ltd on bereconstruct of alimentary tract requires complicated operative
procedures and leads higher operative morbidity and mortal-
ity.3–5 This study determines if there is any difference in the
clinicopathological features and clinical outcome of esopha-
geal cancer with and without a history of distal gastrectomy.half of Surgical Associates Ltd.
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2.1. Clinical data
1411 consecutive patients with primary thoracic esophageal
cancer underwent curative (R0) operation at Jiangsu Province
Tumor hospital, Department of Surgery, Division of Thoracic
Surgery, from June 1997 to June 2007. Among them, 48 patients
had a history of distal gastrectomy and 1328 patients hadn’t
a history of gastrectomy. All specimens were studied histo-
pathologically, pathological evaluation was based on the
TNM classification.62.2. Surgical treatment
All patients underwent radical en bloc esophagectomy (R0)
through a left thoracotomy with a 2-field lymphnode dissec-
tion in the upper abdomen and mediastinum. Reconstruction
of the non-gastrectomized patients was carried out with a gas-
tric tube through the posterior mediastinum route, and esoph-
agogastrostomy was done in the neck under cervical incision
when necessary; for the gastrectomized patients, different
substitution was applied for the reconstruction according to
prior gastric procedures, the size of residual stomach and the
condition of the esophageal lesions (location, length and stage):
2.2.1. Residual gastric tubes with or without splenectomy
While reconstructing, dissociation of the spleen, splenic hilus
and pancreatic tail were undertaken and 2w 4 short gastric
blood vessels be preserved to provide adequate blood supply
for the residual stomach. The residual stomach, afferent and
efferent loops of jejunum was mobilized into the left thorax,
the afferent loop of jejunum close to gastrojejunal anastomo-
sis was transected and the gastric end was closed. The affer-
ent loop is rejoined to the efferent loop (Roux-en-Y method).
The residual stomach, gastrojejunal anastomosis, efferent of
jejunum, spleen, tail of pancreas were all transposed into
the left thoracic cavity. Nine cases (18.8%) were treated
employing this method in this study, and the neck anastomo-
sis was performed in 1 case.
The spleen were too large in 7 case (14.6%), an intrahilar
splenectomy was carried out by individually ligating the
vessels of the splenic hilum, the pancreatic tail was further
mobilized, and the afferent jejunal loop was excised at the
jejuno-gastric anastomotic site. This jejunal loop was then
anastomosed end-to-end to the distal end of the efferent jeju-
nal loop. The completed jejunogastric segment was pulled
above the aortic arch into the apex of thorax, and a anastomo-
sis was performed.
2.2.2. Reversed gastric tubes
The short gastric artery branches locating in the vicinity of the
spleen were divided without mobilizing the pancreatic tail.
The gastrojejunal anastomotic site on the gastric great curva-
ture is then detached and the efferent jejunal loop is anasto-
mosed to the afferent loop, taking care not to injure the left
gastroepiploic arterial arcade. The reversed gastric tube was
constructed with a diameter of 3w 4 cm and a length of
10w 14 cm in 5 cases (10.4%), using the left gastric artery asthe principal blood supply to the gastric remnant, and an
end-to-end anastomosis of the reversed gastric tube to the
esophagus is performed above the aortic arch.
2.2.3. Colon segment interposition
Given its generous vascular supply, the transverse colon or
left colon were used as the esophageal replacement in the
other 27 cases (56.3%). The mobilized colonic segment was
advanced through the esophageal bed and anastomosed by
end to end with the cervical esophagus proximally and the
lower esophagus distally. The choice of short or long colonic
segment for esophageal replacement was based on the length
and location of the esophageal carcinoma.
2.3. Pre-operative treatment and follow-up
Preoperative chemotherapy were performed in 10 and 48 of
gastrectomized and 21 and 1328 of non-gastrectomized
patients, although the survival benefit of the adjuvant thera-
pies has not been significant in our series.
Operative morbidity and mortality were reported and post-
operative patients were surveyed every 3 months by physical
examination and serum tumor markers, every 6 months by
CT scan, abdominal ultrasonography and fiberscopy, until
tumor recurrence was evident. The average follow-up period
was 108.4 months for the gastrectomized patients and
114.7 months for the non-gastrectomized patients.
2.4. Statistical analysis
Continuous variables are expressed as mean  SD, and non-
parametric data as median (range). Statistical differences
between groups were determined by analysis of variance,
Mann–Whitney test, c2 test, and Fisher exact test where
appropriate. Survival was calculated with the Kaplan–Meier
method, and differences were compared with the log-rank
test. Statistical significancewas set at P < 0.05. All calculations
were performed with SPSS11.0.3. Results
Of the 48 gastrectomized patients, there were 45 men and 3
women with an average age of 61.3 years. Twenty-seven
patients underwent a Billroth I and 21 a Billroth II gastrectomy.
The mean interval between previous gastrectomy and diagno-
sis of esophageal cancer was 13.1 years (range 3w 39 years).
3.1. Clinicopathological features
A significant difference in the distribution of tumor location
was observed (Table 1), the proportion of lower-third tumors
in the gastrectomized patients (24 [50.0%] of 48 patients) was
significantly higher compared with that of the non-gastrec-
tomized patients (440 [33.1%] of 1328 patients) (P ¼ 0.006),
this increase was more pronounced after Billroth I vs. Billroth
II gastrectomy (15 [55.6%] vs. 7 [33.3%]). With respect to gross
tumormorphology, esophageal cancers after gastrectomy fre-
quently showed expansive growth pattern (39.6%), while
those without gastrectomy dominantly showed infiltrative
Table 1 – Relationship between history of gastrectomy
and clinicopathological parameters
Parameters Gastrectomized
(n ¼ 48)
Non-gastrectomized
(n ¼ 1328)
P
Age (yr) 57.9  8.8 61.1  9.9 0.028
Male/female 45/3 1178:148 0.285
Albumin level
(g/dL)
3.9  0.5 4.0  0.6 0.653
Body weight (kg) 57.3  9.0 60.0  9.6 0.518
Weight loss (%) 10.3  11.0 11.8  10.0 0.526
Location
Upper 3 (6.3%) 195 (14.7%)
Middle 21 (43.7%) 693 (52.2%)
Lower 24 (50.0%) 440 (33.1%) 0.033
Multiple
oesophageal
cancer
7 (14.6%) 70 (5.3%) 0.006
Histological typea
Well SCC 13 (27.1%) 189 (14.2%)
Mod SCC 16 (33.3%) 536 (40.4%)
Poor SCC 15 (31.3%) 499 (37.6%)
Others 4 (8.3%) 104 (7.8%) 0.098
Gross featureb
Superficial 15 (31.3%) 324 (24.4%)
Expansive 19 (39.6%) 364 (27.4%)
Infiltrative 11 (22.9%) 535 (40.3%)
Unknown 3 (6.3%) 105 (7.9%) 0.012
Primary tumorc
T1 12 (25.0%) 345 (26.0%)
T2 20 (41.7%) 556 (41.9%)
T3 14 (29.2%) 229 (17.2%)
T4 2 (4.2%) 198 (14.9%) 0.096
Lymph node metastasis
Absent 29 (60.4%) 653 (49.2%)
Present 19 (39.6%) 675 (50.8%) 0.126
pTNM staging
I 11 (22.9%) 226 (16.4%)
II 33 (68.8%) 659 (49.6%)
III 4 (8.3%) 392 (29.5%)
IV 0 50 (3.8%) 0.008
a Well-, Mod-, Poor-SCC: well, moderately, and poorly differenti-
ated squamous cell carcinoma, respectively. Others: including ba-
saloid cell carcinoma, small cell carcinoma, adenosquamous cell
carcinoma, adenocarcinoma, carcinosarcoma, and malignant
melanoma.
b Gross feature: ‘‘Expansive’’ includes type 1 (protruding) and type
2 (ulcerative and localized), ‘‘Infiltrative’’ includes type 3 (ulcerative
and infiltrating) and type 4 (diffuse infiltrating).7
c Classification of primary tumor and TNM staging according to
TMN classification (6th edition, 2002).6
Table 2 – Level of tumor distribution according to type of
previous gastrectomy
Tumor location Billroth I
(n ¼ 27)
Billroth II
(n ¼ 21)
P-value
Upper third 2 (7.4%) 1 (4.8%)
Middle third 10 (37.0%) 13 (61.9%)
Lower third 15 (55.6%) 7 (33.3%) 0.231
Multiple oesophageal cancer 3 (11.1%) 4 (19.0%) 0.440
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tumors was squamous cell in 44 (91.7%) of the gastrectomized
patients, and in 1224 (92.2%) of the non-gastrectomized
patients, for those who had lower-third tumors, none of the
gastrectomized patients was adenocarcinoma, while 21
(1.6%) of 1328 non-gastrectomized patients were adenocarci-
nomas, there were no differences in the histological grade of
cancer cells between them.
Multiplicity of esophageal cancer was demonstrated in 7 of
the 48 gastrectomized patients (14.6%), and 70 of the 1334non-gastrectomized patients (5.3%), being significantly more
frequent in gastrectomized patients (P ¼ 0.006). Histopathol-
ogy of all coexisting lesions showed well-differentiated squa-
mous cell carcinoma confined to the superficial mucosal layer.
No significant differences were found in the location of coex-
isting lesions between the oral and anal side of the primary
tumors. Furthermore, squamous epithelial dysplasia was
randomly found around the cancer lesions in all patients.
In the pathological staging, the gastrectomized patients
showed a tendency to harbor cancers of a less advanced path-
ological stage, that is, more stage I and II cases and fewer stage
III and IV cases (P ¼ 0.008). Although superficial cancer (T1)
and node-negative observations were slightly more frequent
for the gastrectomized patients, there were no difference in
the depth of tumor invasion and frequency of lymphnodeme-
tastasis compared with those non-gastrectomized patients.
Next, we compared the clinical background of gastrectom-
ized patients according to disease for gastrectomy, that is
peptic ulcer (n ¼ 27) or gastric cancer (n ¼ 21). The age for
esophagectomy was similar for peptic ulcer group
(57.7  8.7 years) compared with the gastric cancer group
(58.4  9.1 years) (P ¼ 0.737), but the age for gastrectomy was
lower in peptic ulcer patients than in gastric cancer patients
(37.1  10.1 years and 59.4  9.8 years) (P < 0.0001). Thus, the
interval from gastrectomy and esophagectomy was longer
for peptic cancer patients than gastric cancer patients
(24.6  9.2 years vs. 11.5  8.2 years) (P < 0.0001). There was
no difference in the status of esophageal cancers, including
location, histological grade, depth of tumor invasion, lymph
node metastasis, and pTNM stage, between peptic ulcer and
gastric cancer group (data not shown).
As for the gastrectomy procedure, Billroth I was more
frequent for gastric cancer patients while Billroth II was
more frequent for peptic ulcer patients, though there was no
difference between them (P ¼ 0.199). The mean interval be-
tween gastrectomy and diagnosis of esophageal cancer was
somehow shorter in the patients for whom anastomosis had
been performed by Billroth I (11.1  6.1 years) compared with
Billroth II (15.6  9.1 years) (P ¼ 0.048) (Table 2). But the multi-
ple occurrence of esophageal cancer after gastrectomy were 3
and 4 cases respectively, without statistical significance.3.2. Risk of surgical treatment for gastrectomized
esophageal cancer
The substitute organs for reconstruction after esophagectomy
for the gastrectomized patients were the residual gastric tubes
in 8 (19.0%), the reversed gastric tubes in 5 (11.9%), the
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Fig. 1 – Post-operative survival of esophageal cancer
patients with or without history of gastrectomy. Over
survival curves of esophageal cancer patients with
a history of gastrectomy (n[ 48) or without it (n[ 1328)
were plotted by Kaplan–Meier method and their difference
was evaluated by log-rank test. Ten-year survival rate and
P-value were indicated.
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segment in 9 (21.4%). The upper anastomosis was located in
the cervical region in 23 (47.9%) of the 48 gastrectomized
patients and in 245 (18.4%) of the 1328 non-gastrectomized
patients (P < 0.001). The operative time (311.2 86.0 vs. 263.7 
84.9 min; P < 0.001) was longer andmore blood loss (4.38  1.33
vs. 3.57 1.82 IU; P ¼ 0.003) was encountered for esophagec-
tomy after previous gastrectomy.
Within 30 days postoperatively, complications occurred in
16 (33.3%) of 48 gastrectomized patients, including cervical
esophagocolonic anastomotic leaks in 3 cases (6.3%), pulmo-
nary infection in 3 (6.3%), bleeding in 2 (4.2%), vocal cord paral-
ysis in 2 (4.2%), chylothorax in 1 (1.9%), Necrosis of the
substitution in 1 (1.9%), multiple organ dysfunction syndrome
(MODS) in 4 (8.3%), all of whom completely recovered with
medical treatment except one death (1.9%) occurring due to
the necrosis of the substitution. There is no significant differ-
ence in surgical complications between them statistically
(P ¼ 0.066). The post-operative hospital stay was significantly
longer in gastrectomized patients than in non-gastrectomized
ones (median 69 days vs. 40 days, P < 0.001). Anastomotic
leakage was the highest risk factor for prolonging the hospital
stay of the gastrectomized patients, withmedian hospital stay
of 3 patients with leakage being 107 days and that without it
being 45 days (P < 0.001) (Table 3).
3.3. Post-operative survival of gastrectomized
esophageal cancer patients
The follow-up results demonstrated the overall 1, 3, 5, 10-year
survival of gastrectomized and non-gastrectomized patients
were 92%, 64%, 46%, 35% versus 94%, 67%, 40%, 23%, and their
cause-specific 5-year survival were 65% versus 44% (Fig. 1)
(P ¼ 0.992). A total of 88.9% of patients died from their esoph-
ageal cancer, 2.2% from their cardiovascular disease, 2.2%
from their lung disease, and 6.7% from other diseases.
Gender, depth of tumor invasion, lymph node metastasis,
and history of gastrectomywere significant prognostic factors
in the univariate analysis of cause-specific survival (data notTable 3 – Clinical outcome of radical operation for esophageal
Gastrectomized (48 cases)
Operation time (min) 311.2  86.0
Blood loss (ml) 4.38  1.33
Postoperative complicationsa
Anastomotic leak 3 (6.3%)
Infectionb 3 (6.3%)
Bleeding 2 (4.2%)
Chylothorax 1 (2.1%)
Necrosis of the substitution 1 (2.1%)
Vocal cord paralysis 2 (4.2%)
Failure of organ functionc 4 (8.3%)
Hospital stay after operation
Average (median) 65.8  56.2 (47.7 days)
Mortality rate 2 (4.8)
Data are given as number (percentage) of patients.
a These complications are explained in Section 2.
b Including wound infection, thoracic empyema, intraperitoneal sepsis.
c Including failure of heart, pulmonary, renal, liver.shown). In the multivariate analysis, gastrectomy was an in-
dependent factor for favorable prognosis (hazard ratio 1.855,
P ¼ 0.0324) as well as superficial (T1) and node-negative.
Among gastrectomized patients, the disease for gastrec-
tomy, either peptic ulcer or gastric cancer, did not affect the
post-operative survival. The cervical esophagocolic stricture
and dilatation occurred in one case at 1 year after postopera-
tively. The mode of first tumor recurrence was classified as
lymph node metastasis 13 (68%), hematogenic metastasis 3cancer with or without history of gastrectomy
Non-gastrectomized (1328 cases) P-value
263.7  84.9 <0.001
3.57  1.82 0.003
37 (2.8%) 0.161
53 (4.0%) 0.108
24 (1.8%) 0.238
5 (0.4%) 0.078
5 (0.4%) 0.078
64 (4.8%) 0.835
49 (3.7%) 0.031
38.2  24.2 (27.3 days) <0.0001
15 (1.1) 0.061
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both lymph node and hematogenic metastasis). Comparison
with those non-gastrectomized patients (lymph node 56%,
hematogenic 37%, and local 20%, respectively), showed the
tendency hematogenic metastasis to be lesser and lymph
node metastasis to be greater in gastrectomized patients.4. Discussion
The incidence of esophageal cancer patients who have under-
gone distal gastrectomy is increasing recently.3 In this study,
it was 5.8% comparedwith the esophageal carcinoma patients
treated surgically in our hospital in the same period. With
regard to previous diseases for gastrectomy, the proportion
of peptic ulcer and gastric cancer was similar, and the peptic
ulcer was dominant before the introduction of acid suppres-
sive drugs and the recognition of H. pylori in the pathogenesis
of ulcer disease. Recently, the improvement of gastric cancer
treatment should be the greatest reason for the increase of
the gastrectomized esophageal cancer patients.
Owing to a truncal vagotomy, which affects gastric motil-
ity, and postoperative widening of the angle of His, which
may influence lower esophageal sphincter competency,8 the
gastric and duodenal contents, including bile, would reflux
into the esophagus.9 After distal gastrectomy, Esophageal
mucosal changes resulting from persistent regurgitation of
gastric and duodenal contents into the lower esophagus may
occur at higher frequency in patients with partial gastrectomy
than in patients with intact stomach.
It has been demonstrated that bile acid induces cycloxge-
nase-2 (Cox-2), a potentmediator for carcinogenesis, in normal
squamous epithelium and squamous cell carcinoma of the
esophagus,10 and that human squamous cell carcinomas in
the lower thoracic esophagus expresses stronger Cox-2 than
those located in the upper thoracic esophagus.11 Moreover,
Studies using animal models have clearly shown that reflux
of gastroduodenal contents induces esophageal carcinoma, ei-
ther in combinationwith or without exogenous carcinogens.2,3
Considering the high proportion of patients with esopha-
geal cancer in the lower thoracic esophagus who had under-
gone gastrectomy, the presence of esophagitis in patients
with lower thoracic esophageal cancer who had undergone
gastrectomy, and the definite relationship between squamous
dysplasia and carcinoma in the esophagus, referring to the
multicentric occurrence of esophageal carcinomas.12–14 It
may be suggested the gastroesophageal reflex, where the
components have changed to include more bile acid and less
gastric acid after gastrectomy, induces squamous cell carci-
noma in the lower esophagus.
This study showed the high frequency of the multicentric
occurrence of esophageal cancer in the gastrectomized
patients, suggesting gastrectomymay precipitate chronic gas-
troesophageal reflux which can induce the development of
squamous dysplasia and carcinoma at multiple locations.
However, no significant differences were noted in the location
of coexisting cancer lesions between the oral and anal side of
the primary tumor. We cannot explain this finding, but spec-
ulate that factors other than gastroesophageal reflux may bemore important in the development of squamous dysplasia
and/or carcinoma in the esophagus.
The study revealed three factors related to the previous
gastrectomy which significantly influenced the interval be-
tween gastrectomy and the occurrence of esophageal cancer.
Although these factors were not directly related to the occur-
rence of esophageal cancer, they can be discussed in relation
to the carcinogenetic effect of gastrectomy. First, the gastrec-
tomized patients were significantly younger than the non-
gastrectomized patients. We assume that this might provide
indirect evidence of the carcinogenetic effect of gastrectomy
on the subsequent development of esophageal cancer. Sec-
ond, the current study demonstrated a shorter interval
(9.5 years) following gastric cancer and a longer interval
(16.9 years) following gastric ulcer, One explanation for this
may be the additional nodal dissection procedure and/or rela-
tively large resection of the stomach involved in surgery for
gastric cancer, which may result in hastened gastroduodenal
reflux compared with surgery for a gastroduodenal ulcer. An-
other explanation may be the differences in the interval were
probably due to differences in the average ages of patients
presentingwith gastric cancer and peptic ulcer. The difference
of period until the age when esophageal cancer is likely to oc-
cur must be the most important. Third, we observed that the
interval was somehow shorter in patients who had undergone
Billroth I gastrectomy compared with Billroth II procedure, al-
though the difference did not reach its statistical significance
(P ¼ 0.11). The most likely explanation for this is the relatively
high tension on the residual stomach towards the right side in
Billroth I, whichmay result in the deformity of the angle of His
and dysfunction of the gastroesophageal reflux prevention
system. Unfortunately, since we did not preoperatively exam-
ine gastroesophageal reflux or measure pH in the esophagus,
we cannot discuss the carcinogenic effect of reflux any further
on the basis of the findings of the current study.
As to the operative procedure for the gastrectomized
patients, either Billroth I or II is performed, the right gastroepi-
ploic and right gastric arteries are divided, leaving the left
gastric, gastroepiploic and short gastric arteries as the pre-
dominant blood supply to the gastric remnant. In this situa-
tion the likelihood of success of a gastric stump pull-up
above the aortic arch, after ligating and dividing the left gastric
and short gastric arteries during mobilization of the gastric
remnant, is remote. Given the lack of readily available and
viable alternatives, the stomach and colon remain the princi-
pal esophageal substitutes after esophagectomy. Our method
of gastric mobilization included intrahilar splenectomywhich
maintains the integrity of the short gastric and left gastroepi-
ploic vessels. Furthermore, subsequent ligation anddivision of
the left gastric artery and the gastrophrenic ligament increase
the height to which the jejunogastric stump can be elevated.
This not only preserves the short gastric and left gastroepi-
ploic vessels, but also obviates the problem of having to trans-
locate and stabilize the spleen in the pleural cavity in order to
preserve blood supply to the gastric remnant. Detachment of
the afferent jejunal loop also enhanced the distance over
which the gastric stump could be pulled up. There were no
postoperative pleural effusions or gastric emptying disorders
in our cases; none of them has experienced tumor recurrence
in the gastric remnant. Preservation of the gastric remnant
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2þþ and secre-
tion of gastric hormone such as ghrelin.15
In cases of the gastrectomized patients for upper and mid-
dle esophageal carcinoma, the colon is the most commonly
used organ for esophageal reconstruction (ERC). A thorough
preoperative evaluation is an absolute prerequisite for the
successful performance of an ERC reconstruction. The history
of any colonic diseases should be excluded. Contraindications
to the use of ERC include tumors, multiple ulcers or angiop-
athy of the colon; advanced arteriosclerosis in patients with
a history of repetitive vascular thromboses; a history of hema-
tologic or immunodeficiency diseases and the presence of
severe infection with uncontrollable diabetes. Short-segment
colon interposition is suitable for patientswhose tumor length
is less than 3 cm. When excising numerous perpendicular
branches of the peripheral vascular arcades of the colon,
one should be cautious to avoid obstructing the main branch
of the peripheral vascular arcade, as this is critical for elonga-
tion of the vascular pedicle. The advantage of this surgical
procedure is that the esophageal lesion is excised and the
continuity of the esophagus is restored. Most importantly,
the function of the normal gastric cardia is retained so that
there is no occurrence of postoperative gastro-esophageal
reflux,16 the life quality of patients is improved. The long
colonic segment interposition was the most frequent surgical
procedure applied in the gastrectomized patients. The funda-
mental technique required for the successful performance of
ERC is the mobilization and preparation of the pedicled
colonic segment. Methods relating to the choice of the arterial
blood supply for the segment of colon to be used are reported
in other publication.17 We recommend that preoperative mes-
enteric angiography may have been helpful in planning
a more appropriate surgical procedure. When the peduncu-
lated long colonic segment had been successfully isolated,
the permeability and the caliber of the veins must be closely
evaluated during the inspection of the main blood supply of
the colic loop.
Various parameters exhibited more surgical stress of
esophagectomy after gastrectomy than that without history
of gastrectomy.More blood losswas observed during resolving
adhesion in the upper abdominal cavity caused by gastrec-
tomy. Longer operative time was needed due to complicated
reconstruction.Theoperativemortalitywas tolerablealthough
slightly higher in the gastrectomized patients than in the non-
gastrectomized patients. A longer post-operative hospital stay
was mainly due to anastomotic leakage, which was more
frequent and sometime persistent in gastrectomized patients.
The final purpose of this study was to elucidate the clinical
significance of surgical treatment for esophageal cancer
patients after gastrectomy. Surprisingly, despite the greater
surgical stress in esophagectomy for gastrectomized patients
than that for non-gastrectomized patients, the former showed
better overall and cause specific post-operative survival com-
pared with the latter, though without statistical significance.
Gastrectomized patients tended to show less advanced patho-
logical stages, although we do not knowwhether this was due
to the surgeon’s selection or the biological property of this tu-
mor. The former is unlikely, since size of tumor is the same;
rather the latter may be involved since, for example, gastrec-
tomized tumors showed more expansive growth pattern.What is of importance is that in multivariate analysis, gas-
trectomy is an independent prognostic factor, as are sex,
depth of invasion, and lymph nodemetastasis. Kato has spec-
ulated the reason for good prognosis of gastrectomized esoph-
ageal cancer patients as metastasis to abdominal nodes,
especially below the stomach,18 being limited because of alter-
ation of lymphatic flow after gastrectomy.17 In this study, less
tumor recurrence in hematogenic metastasis was observed in
gastrectomized patients andmicroscopic venous involvement
was consistently less frequent in the surgical specimens of
gastrectomized patients than in those of non-gastrectomized
patients (24% vs. 38%). Thismight suggest the different biolog-
ical behaviors of esophageal cancer after gastrectomy. Further
study with a larger number of patients is required to elucidate
this issue.
In summary, the surgical treatment for esophageal cancer
after gastrectomy was complicated but tolerable and can be
expected to have favorable prognosis, the 1-, 3- and 5-year
survival of cases with resection of the esophageal lesions
and reconstruction of the esophagus was 84.6%, 57.5% and
26.7%, respectively. Surgical treatment for these patients is
warranted and it is now under investigation as to whether
or not adjuvant or neoadjuvant use of chemotherapy or radio-
therapy can offer further survival benefit.5. Conclusion
The high incidence of esophageal cancer in the lower esopha-
gusmight suggest the involvement of gastroesophageal reflux
in esophageal carcinogenesis after gastrectomy. Their surgical
treatment was shown to be safe and to offer considerably fa-
vorable prognosis, which should encourage surgeons to at-
tempt this complicated operation.
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